Lexaria Bioscience (LEXX) Long-Term Investments (2014 - 2026)
Lexaria Bioscience (LEXX) posted Long-Term Investments of $64014.0 for Q2 2026, little changed sequentially from $64014.0 in Q1 2026, and little changed YoY from $64014.0 in Q2 2025.
Lexaria Bioscience (LEXX) Long-Term Investments (2014 - 2026) Analysis & Trends
Lexaria Bioscience has reported Long-Term Investments for 6 years, with the latest figure at $64014.0 in Q2 2026.
- Quarterly Long-Term Investments changed 0.0% year-over-year to $64014.0 in Q2 2026, while the trailing twelve-month figure through May 2026 was $64014.0 (changed 0.0% YoY) and the FY2025 annual result came in at $64013.0, up 0.69% from the prior year.
- Long-Term Investments held at $64014.0 in Q2 2026 per LEXX's latest filing, from $64014.0 in the prior quarter.
- Over five years, Long-Term Investments peaked at $64014.0 in Q4 2024 and troughed at $48559.0 in Q3 2023.
- A 4-year average of $62247.8 and a median of $64014.0 in 2024 frame the typical range for Long-Term Investments.
- The sharpest annual moves came in 2024 and 2025: Long-Term Investments jumped 30.92% in 2024, then fell 0.0% in 2025.
- Over 4 years, Long-Term Investments stood at $48559.0 in 2023, then jumped by 31.83% to $64014.0 in 2024, then decreased by 0.0% to $64013.0 in 2025, then climbed by 0.0% to $64014.0 in 2026.
- According to Business Quant data, Long-Term Investments over the past three periods registered $64014.0, $64014.0, and $64013.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.77 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.17 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 372.10 Mn |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - | 64,014.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 64,014.00 |
| Feb 28, 2026 | 64,014.00 |
| Nov 30, 2025 | 64,013.00 |
| Aug 31, 2025 | 64,013.00 |
| May 31, 2025 | 64,014.00 |
| Feb 28, 2025 | 64,014.00 |
| Nov 30, 2024 | 64,014.00 |
| Aug 31, 2024 | 63,575.00 |
| Aug 31, 2023 | 48,559.00 |
| Feb 28, 2015 | 52,662.00 |
| Nov 30, 2014 | 52,662.00 |
| Jul 31, 2014 | 43,149.00 |